API XML

Aop: 275

AOP Title

?


LSETAC AHR gene expression inhibition causes hepatic uroporphyria

Short name:

?

LSETAC uroporphyria

Graphical Representation

?

Click to download graphical representation template

Authors

?


Point of Contact

?


Arthur Author   (email point of contact)

Contributors

?


  • Arthur Author

Status

?

Author status OECD status OECD project SAAOP status
Under development: Not open for comment. Do not cite


This AOP was last modified on June 06, 2019 14:31

?

Revision dates for related pages

Page Revision Date/Time
LSETAC Activation of aryl hydrocarbon receptor June 06, 2019 12:05
LSETAC Inhibition of AHR-mediated activation of gene expression June 06, 2019 12:03
LSETAC Inhibition of uroporphyrinogen decarboxylase (UROD) June 06, 2019 12:04
LSETAC impaired heme biosynthesis June 06, 2019 12:17
LSETAC practice Reduced uroporphyrinogen decarboxylase (UROD) activity June 06, 2019 12:11
LSETAC Accumulation of HCPs June 06, 2019 12:10
LSETAC Hepatic uroporphyria June 06, 2019 12:10
LSETAC AHR Activation leads to LSETAC AHR gene expression inhibition June 06, 2019 12:10
LSETAC AHR Activation leads to LSETAC Accumulation of HCPs June 06, 2019 14:36
LSETAC AHR gene expression inhibition leads to LSETAC Inhibition of UROD June 06, 2019 12:12
LSETAC Inhibition of UROD leads to LSETAC impaired heme biosynthesis June 06, 2019 13:36
Practice Reduced uroporphyrinogen decarboxylase (UROD) activity leads to LSETAC Accumulation of HCPs June 06, 2019 12:16
LSETAC Accumulation of HCPs leads to LSETAC Hepatic uroporphyria June 06, 2019 14:34
LSETAC impaired heme biosynthesis leads to Practice Reduced uroporphyrinogen decarboxylase (UROD) activity June 06, 2019 13:38

Abstract

?



Background (optional)

?



Summary of the AOP

?


Events: Molecular Initiating Events (MIE)

?

Key Events (KE)

?

Adverse Outcomes (AO)

?

Sequence Type Event ID Title Short name
MIE 1524 LSETAC Activation of aryl hydrocarbon receptor LSETAC AHR Activation
KE 1521 LSETAC Inhibition of AHR-mediated activation of gene expression LSETAC AHR gene expression inhibition
KE 1522 LSETAC Inhibition of uroporphyrinogen decarboxylase (UROD) LSETAC Inhibition of UROD
KE 1536 LSETAC impaired heme biosynthesis LSETAC impaired heme biosynthesis
KE 1533 LSETAC practice Reduced uroporphyrinogen decarboxylase (UROD) activity Practice Reduced uroporphyrinogen decarboxylase (UROD) activity
KE 1529 LSETAC Accumulation of HCPs LSETAC Accumulation of HCPs
AO 1530 LSETAC Hepatic uroporphyria LSETAC Hepatic uroporphyria

Relationships Between Two Key Events
(Including MIEs and AOs)

?

Title Adjacency Evidence Quantitative Understanding
LSETAC AHR Activation leads to LSETAC AHR gene expression inhibition adjacent Low Low
LSETAC AHR gene expression inhibition leads to LSETAC Inhibition of UROD adjacent
LSETAC Inhibition of UROD leads to LSETAC impaired heme biosynthesis adjacent
Practice Reduced uroporphyrinogen decarboxylase (UROD) activity leads to LSETAC Accumulation of HCPs adjacent
LSETAC Accumulation of HCPs leads to LSETAC Hepatic uroporphyria adjacent
LSETAC impaired heme biosynthesis leads to Practice Reduced uroporphyrinogen decarboxylase (UROD) activity adjacent
LSETAC AHR Activation leads to LSETAC Accumulation of HCPs non-adjacent Moderate Moderate

Network View

?

 

Stressors

?

Life Stage Applicability

?

Taxonomic Applicability

?

Sex Applicability

?

Overall Assessment of the AOP

?



Domain of Applicability

?


Essentiality of the Key Events

?


Evidence Assessment

?


Quantitative Understanding

?


Considerations for Potential Applications of the AOP (optional)

?



References

?